Clinical Trial Update: A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g [Phase 3]

View source ↗

Summary

This update reports the completion of a Phase 3 safety study of Raptiva (efalizumab) in adults with plaque psoriasis previously enrolled in Study ACD2600g.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis
• Psoriasis

Drugs mentioned

• Raptiva (efalizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Psoriasis | Phase 3 | Status: COMPLETED